KRAS and ovarian carcinoma: In addition, the KRAS-variant was significantly associated with BRCA-uninformative patients who developed ovarian cancer post-menopausally (as estimated by age >52 years), and with BRCA-uninformative patients with a positive family history of breast or ovarian cancer.